Browsing Category
Featured Articles
MenoGeniX Awarded NIH Grant to Fund Phase Ib/IIa Clinical Trial
MenoGeniX announced that the National Institute on Aging (NIA) of the National Institutes of Health (NIH) has awarded the company a Small Business Innovation Research (SBIR) grant for…
Read More...
Read More...
Ferring Signs Global Agreement to Commercialise Novel Gene Therapy for Bladder Cancer Patients
Ferring Pharmaceuticals announced the signing of an agreement giving the company the option to secure global commercialisation rights to nadofaragene firadenovec/Syn3 (rAd-IFN/Syn3), a…
Read More...
Read More...
Novartis receives FDA approval of Tafinlar + Mekinist for adjuvant treatment of BRAF V600-mutant…
Novartis announced that the US Food and Drug Administration (FDA) has approved Tafinlar (dabrafenib) in combination with Mekinist (trametinib) for the adjuvant treatment of patients…
Read More...
Read More...
Merck KGaA, Darmstadt, Germany to Develop Abituzumab in Metastatic Colorectal Cancer with SFJ…
Merck KGaA, Darmstadt, Germany announced a development agreement for investigational molecule abituzumab with SFJ Pharmaceuticals Group (SFJ), a US-based company focused on increasing…
Read More...
Read More...
Exelixis and Invenra Enter Into Collaboration to Discover and Develop Novel Biologics to Treat…
Exelixis announced that it has entered into a collaboration with Invenra, Inc., the Madison, Wisconsin-based biotechnology firm focused on developing next-generation biologics, to…
Read More...
Read More...
Novartis launches FocalView app, providing opportunity for patients to participate in ophthalmology…
Novartis announced the launch of its FocalView app, an ophthalmic digital research platform created with ResearchKit. FocalView aims to allow researchers to track disease progression by…
Read More...
Read More...
AbbVie Submits BLA to FDA for Investigational Treatment Risankizumab for Moderate to Severe Plaque…
AbbVie announced that it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration for risankizumab, an investigational interleukin-23 (IL-23)…
Read More...
Read More...
Concert Pharmaceuticals Completes Enrollment in Phase 2a Trial of CTP-543 in Alopecia Areata
Concert Pharmaceuticals announced that it has completed patient enrollment of its Phase 2a trial evaluating CTP-543 for the treatment of moderate-to-severe alopecia areata. The Company…
Read More...
Read More...
Boehringer Ingelheim R&D pushes to transcend disease boundaries
Family-owned pharmaceutical company Boehringer Ingelheim presented its latest pipeline updates at a Research & Development press conference entitled ‘Transcending Disease…
Read More...
Read More...
Once-daily Trelegy Ellipta gains expanded indication in the US for the treatment of patients with…
GlaxoSmithKline plc and Innoviva announced that the US Food and Drug Administration (FDA) has approved an expanded indication for Trelegy Ellipta (fluticasone…
Read More...
Read More...
AstraZeneca reports results from the ARCTIC trial in third-line non-small cell lung cancer
AstraZeneca and MedImmune announced high-level results from the Phase III ARCTIC trial in patients with locally-advanced or metastatic non-small cell lung cancer (NSCLC) who have…
Read More...
Read More...
Advent International enters into exclusive negotiations to acquire Zentiva
Advent International and Sanofi have entered into exclusive negotiations under which Advent would acquire Zentiva, Sanofi’s European generics business for €1,919 million. Advent’s…
Read More...
Read More...
PhoenixMD Announces Manufacturing Collaboration with WuXi STA to advance PMD-026 toward IND
Phoenix Molecular Designs (PhoenixMD) announced that it has entered into a collaboration with STA Pharmaceutical Co., Ltd (STA), a WuXi AppTec group company, to manufacture the PMD-026…
Read More...
Read More...
Sterling invests £6m in pilot plant facility
Contract development and manufacturing organisation (CDMO) Sterling Pharma Solutions is investing £6m into its pilot plant facility at its UK site to enhance its scale-up and small to…
Read More...
Read More...
bioGO Introduces ‘BioProduction Agility’ to Accelerate Biotech Innovation
Germfree has released bioGO this week in New York at INTERPHEX. The biomanufacturing platform represents a completely new approach to quick and flexible production space. The company…
Read More...
Read More...
FDA approves Tagrisso as 1st-line treatment for EGFR-mutated non-small cell lung cancer
AstraZeneca announced that the US Food and Drug Administration (FDA) has approved Tagrisso (osimertinib) for the 1st-line treatment of patients with metastatic non-small cell…
Read More...
Read More...
Sempre Health and Novo Nordisk Partner to Improve Medication Costs for Patients With Diabetes
Sempre Health announced it's collaborating on a pilot program with Novo Nordisk to add diabetes medications to the Sempre Health affordability & engagement solution. Unlike…
Read More...
Read More...
ProBioGen Signs Second Contract Development Agreement with Tizona Therapeutics for Immuno-Oncology…
ProBioGen AG announced that it has signed a second clinical immuno-oncology development and manufacturing agreement with Tizona Therapeutics, Inc., a privately held immunology company,…
Read More...
Read More...
Artificial antimicrobial peptides could help overcome drug-resistant bacteria
During the past several years, many strains of bacteria have become resistant to existing antibiotics, and very few new drugs have been added to the antibiotic arsenal.
To help…
Read More...
Read More...
GE’s new factory-in-a-box accelerates the production of viral vector based therapeutics
GE Healthcare is launching a ready-to-run factory-in-a-box to speed up the production of viral vector based therapeutics, including viral vector based vaccines, oncolytic viruses and…
Read More...
Read More...